Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives.

doi:10.1016/S0940-2993(98)80034-1

Paper

DOI: 10.1016/S0940-2993(98)80034-1

Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives.

Published Sep 1, 1998 · H. Hoffmann, C. Moore, H. Zimmermann

Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie

UNKNOWN SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

Replacing ethinylestradiol in combined oral contraceptives with natural 17beta-estradiol shows promising results in reducing cardiovascular morbidity and improving overall effectiveness.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1016/S0140-6736(05)64008-1

Balanced view of risks of oral contraceptives

The World Health Organization's review of oral contraceptive risks should emphasize the ongoing improvement in safety and avoid minimizing rare adverse effects.

1997·8citations·W. Spitzer·The Lancet

The Lancet

DOI: 10.1016/S0010-7824(97)00123-6

Modulation of ovarian function by an oral contraceptive containing 30 μg ethinyl estradiol in combination with 2.00 mg dienogest

The oral contraceptive containing 30 g ethinyl estradiol combined with 2.00 mg dienogest effectively suppresses ovarian activity and inhibits ovulation in healthy females.

1997·26citations·J. Spona et al.·Contraception

Contraception

DOI: 10.1016/S0010-7824(96)00201-6

The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days.

The combination of 3.0 mg micronized estradiol and 0.150 mg desogestrel is an effective and safe contraceptive, offering acceptable cycle control, but adding a low dose of desogestrel during the pill-free period did not further suppress ovarian activity or improve the bleeding pattern.

1996·30citations·G. Csemiczky et al.·Contraception

Contraception

DOI: 10.1016/0010-7824(95)00271-5

A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol

Both 20 and 30 g ethinylestradiol-containing gestodene oral contraceptives stimulate both pro-coagulant and fibrinolytic activity, with a trend towards greater fibrinolytic capacity in the 20 g ethinylestradiol group.

1996·57citations·U. Winkler et al.·Contraception

Contraception

DOI: 10.1136/bmj.312.7023.83

Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study

Third generation oral contraceptives have a slightly increased risk of venous thromboembolism compared to second generation products.

1996·569citations·W. Spitzer et al.·BMJ

BMJ

Citations

DOI: 10.1016/j.ejogrb.2024.11.015

Comparative study on the effects of combined oral contraceptives and dienogest in women with endometriosis‑associated chronic pelvic pain.

COCs containing E2 or E4 may be a better treatment for endometriosis-associated chronic pelvic pain than COCs containing EE, and may be a suitable alternative to dienogest for women who do not want to become pregnant.

2024·1citation·Salvatore Caruso et al.·European journal of obstetrics, gynecology, and reproductive biology

European journal of obstetrics, gynecology, and reproductive biology

DOI: 10.1080/13625187.2024.2332302

Correlation of sexual desire with sexual hormone binding globulin and free androgen index in women using combined contraceptives

Women using hormonal contraceptives with ethinylestradiol may experience decreased sexual desire, while this is not observed in those using E2V, 17E2, or E4.

2024·0citations·Salvatore Caruso et al.·The European Journal of Contraception & Reproductive Health Care

The European Journal of Contraception & Reproductive Health Care

DOI: 10.3389/fbioe.2024.1347625

17β-estradiol biosensors based on different bioreceptors and their applications

Biosensors can effectively detect 17-estradiol (E2), benefiting environmental monitoring, food safety, medicine safety, and disease detection.

2024·2citations·Xinyi Wang et al.·Frontiers in Bioengineering and Biotechnology

Frontiers in Bioengineering and Biotechnology

DOI: 10.1089/JWH.2016.5801

Improvement of Low Sexual Desire Due to Antiandrogenic Combined Oral Contraceptives After Switching to an Oral Contraceptive Containing 17β-Estradiol.

Switching to a combined oral contraceptive containing 17-estradiol and nomegestrol acetate improves sexual desire in women with low sexual desire due to ethinylestradiol.

2017·19citations·CarusoSalvatore et al.·Journal of Womens Health

Journal of Womens Health

DOI: 10.1080/17512433.2017.1356718

Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis

Newer oral estrogen-progestin combinations, especially those containing natural estrogens, have minimal hemostatic effects and often remain within the normal range in healthy women.

2016·29citations·M. Farris et al.·Expert Review of Clinical Pharmacology

Expert Review of Clinical Pharmacology